[go: up one dir, main page]

UY31627A1 - Nuevas formas cristalinas del ácido 4-[4-(2-adamantilcarbamoíl)-5-ter-butil-pirazol-1-il]benzoico - Google Patents

Nuevas formas cristalinas del ácido 4-[4-(2-adamantilcarbamoíl)-5-ter-butil-pirazol-1-il]benzoico

Info

Publication number
UY31627A1
UY31627A1 UY031627A UY31627A UY31627A1 UY 31627 A1 UY31627 A1 UY 31627A1 UY 031627 A UY031627 A UY 031627A UY 31627 A UY31627 A UY 31627A UY 31627 A1 UY31627 A1 UY 31627A1
Authority
UY
Uruguay
Prior art keywords
adamantilcarbamoíl
benzoico
butil
pirazol
ter
Prior art date
Application number
UY031627A
Other languages
English (en)
Inventor
Gary Peter Tomkinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2008/000454 external-priority patent/WO2008099145A1/en
Application filed filed Critical
Publication of UY31627A1 publication Critical patent/UY31627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen nuevas formas cristalinas del ácido 4-[4-2-adamantilcarbamoil)-5-ter-butil-pirazol-1-il]benzoico, su utilización en la inhibición de la enzima 11B(Beta)HSD1, procedimientos para obtenerlas y composiciones farmacéuticas que las contienen.
UY031627A 2008-02-04 2009-02-03 Nuevas formas cristalinas del ácido 4-[4-(2-adamantilcarbamoíl)-5-ter-butil-pirazol-1-il]benzoico UY31627A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PK10808 2008-02-04
PCT/GB2008/000454 WO2008099145A1 (en) 2007-02-12 2008-02-11 Pyrazole derivatives as 11-beta-hsd1 inhibitors
US8229308P 2008-07-21 2008-07-21

Publications (1)

Publication Number Publication Date
UY31627A1 true UY31627A1 (es) 2009-08-31

Family

ID=42782026

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031627A UY31627A1 (es) 2008-02-04 2009-02-03 Nuevas formas cristalinas del ácido 4-[4-(2-adamantilcarbamoíl)-5-ter-butil-pirazol-1-il]benzoico

Country Status (15)

Country Link
US (3) US7951833B2 (es)
EP (1) EP2244705A1 (es)
JP (1) JP2011510966A (es)
KR (1) KR20100126306A (es)
CN (1) CN101969946A (es)
AR (1) AR070560A1 (es)
AU (1) AU2009211215B2 (es)
CA (1) CA2713409A1 (es)
MX (1) MX2010008583A (es)
PE (1) PE20091456A1 (es)
RU (1) RU2010133483A (es)
SA (1) SA109300090B1 (es)
TW (1) TW200946506A (es)
UY (1) UY31627A1 (es)
WO (1) WO2009098501A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
TW200827346A (en) * 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
JP4671369B2 (ja) 2007-05-18 2011-04-13 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する含窒素複素環誘導体
CN101969946A (zh) * 2008-02-04 2011-02-09 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸的新晶型
EP2271629A1 (en) * 2008-04-22 2011-01-12 AstraZeneca AB Substituted pyrimidin-5-carboxamides 281
JP2012516327A (ja) * 2009-01-30 2012-07-19 アストラゼネカ アクチボラグ カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10689387B2 (en) * 2016-10-28 2020-06-23 Astrazeneca Ab Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) * 1978-02-21 1981-03-27 Delalande Sa
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
AU2004265299B2 (en) 2003-08-07 2008-05-01 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
BRPI0510623A (pt) 2004-05-06 2007-10-30 Pfizer compostos de derivados de prolina e morfolina
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
EP1928840B1 (en) 2005-04-05 2011-08-10 F. Hoffmann-La Roche AG 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006132197A1 (ja) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
KR100970294B1 (ko) * 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
CN101312951A (zh) 2005-11-21 2008-11-26 盐野义制药株式会社 具有Ⅰ型11β羟基类固醇脱氢酶抑制活性的杂环化合物
RS54216B1 (sr) * 2006-03-22 2015-12-31 F. Hoffmann-La Roche Ag. Pirazoli kao 11-beta-hsd-1
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
JP4671369B2 (ja) 2007-05-18 2011-04-13 塩野義製薬株式会社 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する含窒素複素環誘導体
WO2009010416A2 (en) 2007-07-17 2009-01-22 F. Hoffmann-La Roche Ag Inhibitors of 11b-hydroxysteroid dehydrogenase
CA2703781A1 (en) * 2007-11-06 2009-05-14 Astrazeneca Ab 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465
CN101969946A (zh) * 2008-02-04 2011-02-09 阿斯利康(瑞典)有限公司 4-[4-(2-金刚烷基氨基甲酰基)-5-叔丁基-吡唑-1-基]苯甲酸的新晶型
EP2271629A1 (en) 2008-04-22 2011-01-12 AstraZeneca AB Substituted pyrimidin-5-carboxamides 281
TW201118085A (en) * 2009-10-20 2011-06-01 Astrazeneca Ab Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-β-HSD1

Also Published As

Publication number Publication date
EP2244705A1 (en) 2010-11-03
MX2010008583A (es) 2010-08-30
JP2011510966A (ja) 2011-04-07
US7951833B2 (en) 2011-05-31
AR070560A1 (es) 2010-04-21
WO2009098501A1 (en) 2009-08-13
CA2713409A1 (en) 2009-08-13
PE20091456A1 (es) 2009-10-24
AU2009211215A1 (en) 2009-08-13
RU2010133483A (ru) 2012-03-20
KR20100126306A (ko) 2010-12-01
SA109300090B1 (ar) 2011-10-03
TW200946506A (en) 2009-11-16
CN101969946A (zh) 2011-02-09
US20110028529A1 (en) 2011-02-03
AU2009211215B2 (en) 2011-11-03
US20110028530A1 (en) 2011-02-03
US20090221660A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
UY31627A1 (es) Nuevas formas cristalinas del ácido 4-[4-(2-adamantilcarbamoíl)-5-ter-butil-pirazol-1-il]benzoico
ECSP11011469A (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
ECSP11011210A (es) Sal de hemi-fumarato del ácido 1-[4-[1-(4-ciclohexil-3-trifluoro-metil-benciloxi-imino)-etil]-2-etil-bencil]-azetidin-3-carboxílico
CL2011002359A1 (es) Compuesto atropisomero opticamente activo de 2-(((6-amino-9h-purin-9il)metil)-5-metil-3-o-tolilquinazolin-4(3h)-ona, inhibidor de las isoformas pdk, particularmente la isoforma delta; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, rinitis, alergica, asma, dermatitis atopica, entre otras.
CO6321253A2 (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4- amino-5- fluoro-3-[5-(4-metil-piperazin-1-il)1h-bencimidazol-2-il]-quinolin-2(1h)-ona
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
MX2018001531A (es) Medio de cultivo celular complementado con taurina y metodos de uso.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
CL2008000911A1 (es) Compuestos derivados de pirimidina, inhibidores de prostaglandina d2; composicion farmaceutica; y uso para tratar un trastorno alergico o inflamatorio tal como rinitis alergica, asma y epoc.
ECSP109917A (es) Nuevos derivados de ácido azabifenilaminobenzoico
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
CL2007001972A1 (es) Ester isopropilico del acido 4-[6-(6-metanosulfonil-2-metilpiridin-3-ilamino)-5-metilpirimidin-4-iloxi]piperidin-1-carboxilico, moduladores del metabolismo; composicion farmaceutica; y su uso para tratar trastornos metabolicos.
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
CU20130044A7 (es) Proceso para la preparación de inhibidores de pan-cdk de fórmula (i), e intermediarios de la preparación
GT200600227A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
CL2012000450A1 (es) Compuestos derivados de isoxazolidina de glucocorticoides, de la serie de los glucocorticoides; composicion farmaceutica; combinacion farmaceutica; proceso para su preparacion; y uso para disminuir la cantidad, acividad y movimiento de las celulas inflamatorias.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
ECSP11011503A (es) Compuestos carboxamida y su uso como inhibidores de calpaína.
MA32818B1 (fr) Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c
MX350158B (es) Diacilhidrazina cristalina y sus usos.
PA8797801A1 (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas
MX382563B (es) Formas cristalinas de bilastina y procedimientos para su preparacion.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180823